Amgen investigational therapy, AMG 162, increased bone mineral density with twice yearly...( SEATTLE (October 03 2004) Amgen Inc. ...)

SEATTLE (October 03, 2004) Amgen Inc. (NASDAQ: AMGN), the world's largest biotechnology company, today announced that at all doses studied, twice yearly injections of AMG 162, the company's investigational therapy for bone loss, significantly increased bone mineral density (BMD) at the total hip compared with placebo at 12 months. AMG 162, at all doses, also increased total hip BMD, similar to or greater than that resulting from FOSAMAX® (alendronate)* treatment in the same time frame.

The one year results of the ongoing multi-center, Phase 2, dose ranging trial in healthy postmenopausal women with low BMD were presented at the American Society for Bone and Mineral Research (ASBMR) 26th Annual Meeting in Seattle. This double blind trial was designed to evaluate the safety and efficacy of AMG 162 compared with placebo with an open label cohort comparison to FOSAMAX®.

"This study suggests that AMG 162 significantly improves bone mineral density in postmenopausal patients experiencing bone loss," said Michael McClung, MD, FACE, principal investigator of the AMG 162 study and founding director of the Oregon Osteoporosis Center in Portland. "The medical community should be very encouraged by these data that suggest AMG 162, when administered twice a year, may offer a promising alternative for the treatment of osteoporosis."

"With the development of AMG 162, Amgen scientists have validated an entirely new pathway and novel mechanism of action for addressing conditions associated with bone loss," said Beth Seidenberg, MD, chief medical officer and senior vice president of global development, Amgen. "These Phase 2 results with our investigational agent are very compelling and give us great confidence as we actively enroll and initiate our pivotal trial."

The effects of AMG 162 (at 60 mg twice yearly) at the total hip BMD were significantly (p<0.001) greater than FOSAMAX® (at 70 mg once weekly) at 12 months. AMG 162 across
'"/>


3-Oct-2004

Page: 1 2 3 4
Related biology news :

1. Eduardo Slatopolsky honored with 2007 ISN Amgen International Prize
2. 2007 Amgen Biochemical Engineering Award
3. Amgen launches Aranesp prefilled Sureclick autoinjector for treatment of anemia
4. Amgens decision to block reinstatement of GDNF is faulted by a leading Parkinsons advocacy group
5. ASBMB-Amgen Award Lecture to focus on orphan nuclear receptors
6. FUZEON with investigational HIV drug results in remarkable number of patients achieving undetectable
7. Providence health system shows investigational osteoporosis therapy increases bone mineral density
8. Sitagliptin, a new investigational treatment for type 2 diabetes, may offer new hope for patients
9. Combining NSAIDs with chemotherapy, radiation may improve cancer treatment
10. Chromosomal tests can determine brain tumor therapy, outcomes, Jefferson oncologists find
11. New treatment option breaks Leukemias resistance to chemotherapy, radiation therapy